PF-Atlas › Clinical Trials › NCT01131507

PR-018: An Open-Label, Safety Extension of Study PR-011

EUR-1008 · Phase 4

Registry ID

NCT01131507

Phase

Phase 4

Status

Completed

Drug / intervention

EUR-1008 (APT-1008)

Sponsor

Forest Laboratories

Start

2010-07

Enrollment

Locations

About this trial

A study to evaluate long term safety and effect on ability to thrive of EUR-1008 (APT-1008) 3,000 lipase units (Zenpep® \[pancrelipase\] delayed release capsules) in infants with exocrine pancreatic insufficiency (EPI) due to cystic fibrosis (CF).

View NCT01131507 on ClinicalTrials.gov →

Explore related

All EUR-1008 trials All IPF trials

Medical disclaimer. This page summarizes public trial data for NCT01131507 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.